A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
NCT ID: NCT03104374
Last Updated: 2025-09-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
642 participants
INTERVENTIONAL
2017-05-01
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
NCT03104400
A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
NCT04758117
Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis
NCT00534313
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
NCT01860976
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00338754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All participants in Period 1 who were randomized to receive Placebo up to 24 weeks were pooled for the assessment of all outcome measures. All participants receiving upadacitinib 30 mg QD during Period 2 were switched to upadacitinib 15 mg QD following a protocol amendment and were pooled for AE reporting.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Upadacitinib 15 mg
Administered once daily.
Upadacitinib
Oral tablet
Placebo / Upadacitinib 30 mg
Administered once daily.
Placebo
Oral tablet
Upadacitinib
Oral tablet
Upadacitinib 30 mg
Administered once daily.
Upadacitinib
Oral tablet
Placebo / Upadacitinib 15 mg
Administered once daily.
Placebo
Oral tablet
Upadacitinib
Oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Oral tablet
Upadacitinib
Oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has active disease at Baseline defined as \>= 3 tender joints (based on 68 joint counts) and \>= 3 swollen joints (based on 66 joint counts) at Screening and Baseline Visits
* Diagnosis of active plaque psoriasis or documented history of plaque psoriasis
* Participant has had an inadequate response (lack of efficacy after a minimum 12 week duration of therapy) or intolerance to treatment with at least 1 bDMARD.
Exclusion Criteria
* Current treatment with \> 2 non-biologic DMARDs or use of DMARDs other than Methotrexate (MTX), Sulfasalazine (SSZ), Leflunomide (LEF), apremilast, Hydroxychloroquine (HCQ), bucillamine or iguratimod or use of MTX in combination with LEF at Baseline.
* History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than PsA (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus). Prior history of reactive arthritis or axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis is permitted if documentation of change in diagnosis to PsA or additional diagnosis of PsA is made. Prior history of fibromyalgia is permitted if documentation of change in diagnosis to PsA or documentation that the diagnosis of fibromyalgia was made incorrectly.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Medical Group, PC /ID# 159836
Mobile, Alabama, United States
Arizona Arthritis & Rheumatology Research, PLLC /ID# 160047
Mesa, Arizona, United States
Sun Valley Arthritis Center Ltd. /ID# 161203
Peoria, Arizona, United States
Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 160006
Phoenix, Arizona, United States
Osteoporosis Medical Center /ID# 161411
Beverly Hills, California, United States
Covina Arthritis Clinic /ID# 159919
Covina, California, United States
Triwest Research Associates /ID# 159915
El Cajon, California, United States
Duplicate_Providence Medical Foundation /ID# 160005
Fullerton, California, United States
C.V. Mehta MD, Med Corporation /ID# 161192
Hemet, California, United States
Care Access Research, Huntington Beach /ID# 160049
Huntington Beach, California, United States
Purushotham & Akther Kotha MD, Inc /ID# 159834
La Mesa, California, United States
Stanford University School of Med /ID# 161402
Stanford, California, United States
Inland Rheum Clin Trials Inc. /ID# 159839
Upland, California, United States
Medvin Clinical Research /ID# 160045
Whittier, California, United States
Denver Arthritis Clinic /ID# 159899
Denver, Colorado, United States
Colorado Arthritis Associates /ID# 159856
Lakewood, Colorado, United States
Duplicate_Arthritis & Rheumatic Disease Specialties /ID# 161409
Aventura, Florida, United States
International Medical Research /ID# 160051
Daytona Beach, Florida, United States
Precision Research Organization /ID# 161293
Miami Lakes, Florida, United States
Duplicate_Suncoast Clinical Research /ID# 161417
New Port Richey, Florida, United States
Millennium Research /ID# 159833
Ormond Beach, Florida, United States
Arthritis Center, Inc. /ID# 163463
Palm Harbor, Florida, United States
Gulf Region Clinical Res Inst /ID# 159860
Pensacola, Florida, United States
Sarasota Arthritis Center /ID# 159854
Sarasota, Florida, United States
BayCare Medical Group /ID# 161405
St. Petersburg, Florida, United States
West Broward Rheumatology Associates /ID# 161412
Tamarac, Florida, United States
Clinical Research of West Florida - Tampa /ID# 160069
Tampa, Florida, United States
Clinical Research of West Florida, Inc /ID# 159840
Tampa, Florida, United States
USF Health Morsani Center for /ID# 161291
Tampa, Florida, United States
BayCare Medical Group, Inc. /ID# 159912
Tampa, Florida, United States
Florida Medical Clinic /ID# 160013
Zephyrhills, Florida, United States
Jefrey D. Lieberman, MD, P.C. /ID# 159842
Decatur, Georgia, United States
Atlanta Research Center for Rheumatology /ID# 161201
Marietta, Georgia, United States
Velocity Clinical Research - Boise /ID# 159922
Meridian, Idaho, United States
Great Lakes Clinical Trials /ID# 163438
Chicago, Illinois, United States
Deerbrook Medical Associates /ID# 159815
Libertyville, Illinois, United States
Duplicate_Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 160068
Skokie, Illinois, United States
The Arthritis & Diabetes Clinic, Inc. /ID# 161294
Monroe, Louisiana, United States
Arthritis Treatment Center /ID# 160053
Frederick, Maryland, United States
The Center for Rheumatology and Bone Research /ID# 159900
Wheaton, Maryland, United States
Clinical Pharmacology Study Group /ID# 158712
Worcester, Massachusetts, United States
Clinvest Research LLC /ID# 161208
Springfield, Missouri, United States
Westroads Clinical Research /ID# 160004
Omaha, Nebraska, United States
Atlantic Coast Research /ID# 159810
Toms River, New Jersey, United States
Duplicate_Arthritis and Osteo Assoc /ID# 160015
Las Cruces, New Mexico, United States
Center for Rheumatology LLP /ID# 167046
Albany, New York, United States
St. Lawrence Health System /ID# 159857
Potsdam, New York, United States
DJL Clinical Research, PLLC /ID# 161414
Charlotte, North Carolina, United States
Physicians East, PA /ID# 159898
Greenville, North Carolina, United States
Shanahan Rheuma & Immuno /ID# 160012
Raleigh, North Carolina, United States
PMG Research of Wilmington LLC /ID# 161403
Wilmington, North Carolina, United States
Trinity Health Med Arts Clinic /ID# 159811
Minot, North Dakota, United States
STAT Research, Inc. /ID# 161416
Vandalia, Ohio, United States
Health Research of Oklahoma /ID# 159913
Oklahoma City, Oklahoma, United States
Altoona Ctr Clinical Res /ID# 159861
Duncansville, Pennsylvania, United States
University of Pittsburgh MC /ID# 161193
Pittsburgh, Pennsylvania, United States
Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 163462
Summerville, South Carolina, United States
Rheumatology Consultants, PLLC /ID# 161408
Knoxville, Tennessee, United States
Dr. Ramesh Gupta /ID# 160067
Memphis, Tennessee, United States
Tekton Research, Inc. /ID# 160008
Austin, Texas, United States
Diagnostic Group /ID# 161406
Beaumont, Texas, United States
Arthritis and Osteoporosis Clinic Of Brazos Valley /ID# 163439
College Station, Texas, United States
Adriana Pop-Moody MD Clinic PA /ID# 160009
Corpus Christi, Texas, United States
Metroplex Clinical Research /ID# 159818
Dallas, Texas, United States
Rheumatic Disease Clin Res Ctr /ID# 161252
Houston, Texas, United States
Accurate Clinical Research /ID# 160052
Houston, Texas, United States
P&I Clinical Research /ID# 159837
Lufkin, Texas, United States
SW Rheumatology Res. LLC /ID# 160014
Mesquite, Texas, United States
DM Clinical Research - Tomball /ID# 161753
Tomball, Texas, United States
Arthritis & Osteoporosis Clinic /ID# 161400
Waco, Texas, United States
Arthritis Clinic of N. VA, P.C /ID# 159858
Arlington, Virginia, United States
Duplicate_Swedish Medical Center /ID# 159918
Seattle, Washington, United States
Emeritus Research Sydney /ID# 166751
Botany, New South Wales, Australia
The Queen Elizabeth Hospital /ID# 200840
Woodville South, South Australia, Australia
Box Hill Hospital /ID# 166752
Box Hill, Victoria, Australia
Heidelberg Repatriation Hospital /ID# 167441
Heidelberg West, Victoria, Australia
ReumaClinic /ID# 164214
Genk, Limburg, Belgium
UZ Gent /ID# 164210
Ghent, Oost-Vlaanderen, Belgium
CIP - Centro Internacional de Pesquisa /ID# 161808
Goiânia, Goiás, Brazil
Faculdade de Medicina do ABC /ID# 163489
Santo André, La Spezia, Brazil
Hospital de Clínicas da Universidade Federal de Uberlândia /ID# 161794
Uberlândia, Minas Gerais, Brazil
Hospital de Clinicas de Porto Alegre /ID# 161795
Porto Alegre, Rio Grande do Sul, Brazil
LMK Sevicos Medicos S/S /ID# 161806
Porto Alegre, Rio Grande do Sul, Brazil
Duplicate_Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 163317
Ribeirão Preto, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 161793
São Paulo, , Brazil
Percuro Clinical Research, Ltd /ID# 157835
Victoria, British Columbia, Canada
CIADS Research Co Ltd /ID# 157843
Winnipeg, Manitoba, Canada
The Waterside Clinic /ID# 157838
Orillia, Ontario, Canada
Groupe de Recherche en Maladies Osseuses Inc /ID# 157836
Sainte-Foy, Quebec, Canada
Centre de Recherche Musculo-Squelettique /ID# 163557
Trois-Rivières, Quebec, Canada
CTR Estudios Clinicos /ID# 206038
Providencia, Aysén, Chile
Duplicate_Clinica Dermacross /ID# 169537
Santiago, , Chile
Duplicate_Centro Internacional de Estudios Clinicos /ID# 169543
Santiago, , Chile
Prosalud Ltda. /ID# 169542
Santiago, , Chile
Revmatologie Bruntal, s.r.o /ID# 159632
Prostějov, , Czechia
Medical Plus, s.r.o. /ID# 159631
Uherské Hradiště, , Czechia
Hopital Saint Joseph /ID# 163755
Marseille, Bouches-du-Rhone, France
CHU Toulouse /ID# 163743
Toulouse, Occitanie, France
Centre Hospitalier du Mans /ID# 163746
Le Mans, Sarthe, France
CHRU Tours - Hopital Trousseau /ID# 163772
Chambray-lès-Tours, , France
Duplicate_CHU-Hospital Henri Mondor /ID# 163895
Créteil, , France
Duplicate_AP-HP - Hopital Lariboisiere /ID# 163773
Paris, , France
General Hospital of Athens Laiko /ID# 163474
Athens, Attica, Greece
Naval Hospital of Athens /ID# 163495
Athens, , Greece
Reg Gen Univ Hosp Larissa /ID# 163493
Larissa, , Greece
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 162573
Győr, Győr-Moson-Sopron, Hungary
Vital Medicina Kft /ID# 162571
Veszprém, Veszprém megye, Hungary
Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 170911
Budapest, , Hungary
Revita Reumatologiai Rendelo /ID# 162575
Budapest, , Hungary
Obudai Egeszsegugyi Centrum Kft. /ID# 162576
Budapest, , Hungary
Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 162572
Debrecen, , Hungary
MÁV Kórház /ID# 162574
Szolnok, , Hungary
Azienda Ospedaliera Universitaria Federico II /ID# 202410
Napoli, L Aquila, Italy
Duplicate_Fondazione Policlinico Universitario Campus Bio-Medico di Roma /ID# 164123
Rome, Roma, Italy
Duplicate_Fondazione PTV Policlinico Tor Vergata /ID# 162749
Rome, Roma, Italy
Duplicate_Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 162748
Ancona, , Italy
Duplicate_A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 164126
Catania, , Italy
Duplicate_AOU Arcispedale Sant Anna di /ID# 164127
Cona, , Italy
ASST Gaetano Pini/Presidio Ospedaliero Pini /ID# 164125
Milan, , Italy
Duplicate_Azienda Unita Sanitaria Locale/IRCCS /ID# 162751
Reggio Emilia, , Italy
Daido Hospital /ID# 163639
Nagoya, Aichi-ken, Japan
Nagoya City University Hospital /ID# 162563
Nagoya, Aichi-ken, Japan
Fukuoka University Hospital /ID# 161774
Fukuoka, Fukuoka, Japan
Duplicate_Kitakyushu Municipal Medical Center /ID# 163516
Kitakyushu-shi, Fukuoka, Japan
Hospital of the University of Occupational and Environmental Health, Japan /ID# 161472
Kitakyushu-shi, Fukuoka, Japan
Asahikawa Medical University Hospital /ID# 200684
Asahikawa-shi, Hokkaido, Japan
Mie University Hospital /ID# 162085
Tsu, Mie-ken, Japan
Tohoku University Hospital /ID# 164035
Sendai, Miyagi, Japan
Oribe Clinic of Rheumatism and Medicine /ID# 163704
Ōita, Oita Prefecture, Japan
Kansai Medical University Hospital /ID# 162081
Hirakata-shi, Osaka, Japan
National Hospital Organization Osaka Minami Medical Center /ID# 162589
Kawachinagano Shi, Osaka, Japan
Osaka Metropolitan University Hospital /ID# 162082
Osaka, Osaka, Japan
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 161773
Osaka, Osaka, Japan
Juntendo University Hospital /ID# 162089
Bunkyo-ku, Tokyo, Japan
St.Luke's International Hospital /ID# 162013
Chuo-ku, Tokyo, Japan
Keio University Hospital /ID# 162130
Shinjuku-ku, Tokyo, Japan
Medisch Centrum Leeuwarden /ID# 163049
Leeuwarden, South Holland, Netherlands
Duplicate_Erasmus Medisch Centrum /ID# 163052
Rotterdam, South Holland, Netherlands
Maasstad Ziekenhuis /ID# 163050
Rotterdam, South Holland, Netherlands
Sint Maartenskliniek /ID# 163703
Ubbergen, , Netherlands
Duplicate_Middlemore Hospital /ID# 166411
Otahuhu, Auckland, New Zealand
Timaru Medical Specialists Ltd /ID# 166410
Timaru, Canterbury, New Zealand
Waikato Hospital /ID# 166412
Hamilton, Waikato Region, New Zealand
Porter Rheumatology Ltd /ID# 200422
Nelson, , New Zealand
Duplicate_Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE /ID# 165897
Vila Nova de Gaia, Porto District, Portugal
Unidade Local de Saúde do Alto Minho, EPE - Hospital Conde de Bertiandos /ID# 165898
Ponte de Lima, Viana do Castelo District, Portugal
Instituto Portugues De Reumatologia /ID# 165894
Lisbon, , Portugal
Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Egas Moniz /ID# 165896
Lisbon, , Portugal
Unidade Local de Saude de Santa Maria, EPE /ID# 165895
Lisbon, , Portugal
Alma M. Cruz Santana, MD-Private practice /ID# 163308
Carolina, , Puerto Rico
Ponce Medical School Foundation /ID# 163918
Ponce, , Puerto Rico
GCM Medical Group PSC /ID# 163716
San Juan, , Puerto Rico
Duplicate_Ajou University Hospital /ID# 163893
Suwon, Gyeonggido, South Korea
Duplicate_Inha University Hospital /ID# 163892
Junggu, Incheon Gwang Yeogsi, South Korea
Hospital Clinico Universitario Virgen de la Arrixaca /ID# 163138
El Palmar, Murcia, Spain
Duplicate_Hospital Universitario A Coruna - CHUAC /ID# 161019
A Coruña, , Spain
Duplicate_Hospital Universitario Reina Sofia /ID# 170764
Córdoba, , Spain
Hospital Campus de la Salud /ID# 170768
Granada, , Spain
Hospital Universitario Ramon y Cajal /ID# 161020
Madrid, , Spain
Royal United Hospitals Bath /ID# 161054
Bath, Bath And North East Somerset, United Kingdom
Barts Health NHS Trust /ID# 161053
London, London, City of, United Kingdom
Guys and St Thomas NHS Foundation Trust /ID# 161063
London, London, City of, United Kingdom
Duplicate_NHS Greater Glasgow and Clyde /ID# 162712
Glasgow, , United Kingdom
Duplicate_Bedfordshire Hospitals NHS Foundation Trust /ID# 162713
Luton, , United Kingdom
Duplicate_Christchurch University Hospitals Dorset NHS University Hospitals Dors /ID# 162711
Poole, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.
Cantini F, Marchesoni A, Novelli L, Gualberti G, Marando F, McDearmon-Blondell EL, Gao T, McGonagle D, Salvarani C. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials. Rheumatology (Oxford). 2024 Nov 1;63(11):3146-3154. doi: 10.1093/rheumatology/keae057.
Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20.
Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392.
Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, Carter K, Li Y, McCaskill R, McDearmon-Blondell E, Wung P, Tillett W. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clin Exp Rheumatol. 2023 Nov;41(11):2286-2297. doi: 10.55563/clinexprheumatol/8l7bbk. Epub 2023 Jul 5.
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
Mease P, Kavanaugh A, Gladman D, FitzGerald O, Soriano ER, Nash P, Feng D, Lertratanakul A, Douglas K, Lippe R, Gossec L. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatol Ther. 2022 Aug;9(4):1181-1191. doi: 10.1007/s40744-022-00449-6. Epub 2022 May 23.
Burmester GR, Winthrop K, Blanco R, Nash P, Goupille P, Azevedo VF, Salvarani C, Rubbert-Roth A, Lesser E, Lippe R, Lertratanakul A, Mccaskill RM, Liu J, Ruderman EM. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatol Ther. 2022 Apr;9(2):521-539. doi: 10.1007/s40744-021-00410-z. Epub 2021 Dec 30.
Nash P, Richette P, Gossec L, Marchesoni A, Ritchlin C, Kato K, McDearmon-Blondell EL, Lesser E, McCaskill R, Feng D, Anderson JK, Ruderman EM. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022 Aug 3;61(8):3257-3268. doi: 10.1093/rheumatology/keab905.
Strand V, Van den Bosch F, Ranza R, Leung YY, Drescher E, Zueger P, Saffore CD, Lertratanakul A, Lippe R, Nash P. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Rheumatol Ther. 2021 Dec;8(4):1827-1844. doi: 10.1007/s40744-021-00377-x. Epub 2021 Oct 18.
Muensterman E, Engelhardt B, Gopalakrishnan S, Anderson JK, Mohamed MF. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials. Clin Transl Sci. 2022 Jan;15(1):267-278. doi: 10.1111/cts.13146. Epub 2021 Oct 27.
Mease PJ, Lertratanakul A, Papp KA, van den Bosch FE, Tsuji S, Dokoupilova E, Keiserman MW, Bu X, Chen L, McCaskill RM, Zueger P, McDearmon-Blondell EL, Pangan AL, Tillett W. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatol Ther. 2021 Jun;8(2):903-919. doi: 10.1007/s40744-021-00305-z. Epub 2021 Apr 28.
Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, McCaskill RM, Zueger P, Pangan AL, Tillett W. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021 Mar;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870. Epub 2020 Dec 3.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-004152-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
M15-554
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.